Biotech Values

[DewDiligence]

MNTA’s 3Q11 cash operating expenses excluding R&D revenue (which is essentially reimbursement from NVS) and excluding MNTA’s royalties to MIT* were $17.5M, according to today's CC. This amount is within the $15-18M quarterly range that MNTA has given in prior guidance (#msg-65880685).

*3Q11 royalties to MIT of $2.9M were boosted by the $10M milestone payment MNTA received from NVS for the first anniversary of the Lovenox launch; they will be lower in subsequent quarters.